Financial reports
20-F
2022 FY
Annual report (foreign)
26 Apr 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
28 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
10-Q
2021 Q2
Quarterly report
12 Aug 21
10-Q
2021 Q1
Quarterly report
13 May 21
10-K/A
2020 FY
Annual report (amended)
29 Apr 21
10-K
2020 FY
Annual report
30 Mar 21
Current reports
8-K
Submission of Matters to a Vote of Security Holders
21 Mar 23
8-K
Entry into a Material Definitive Agreement
31 Jan 23
8-K
Casi Pharmaceuticals Announces Third Quarter 2022 Financial Results
14 Nov 22
8-K
Casi Pharmaceuticals Announces Exit of Juventas Investment to Strengthen Balance Sheet
23 Sep 22
8-K
Casi Pharmaceuticals Announces Second Quarter 2022 Financial Results
12 Aug 22
8-K
Casi Pharmaceuticals Announces Reverse Stock Split
26 May 22
8-K
Other Events
25 May 22
8-K
Submission of Matters to a Vote of Security Holders
25 May 22
8-K
Entry into a Material Definitive Agreement
24 May 22
8-K
Casi Pharmaceuticals Enters into Sublicense Agreement
24 May 22
Registration and prospectus
15-12G
Securities registration termination
22 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 23
POS AM
Prospectus update (post-effective amendment)
21 Mar 23
424B5
Prospectus supplement for primary offering
29 Oct 21
S-8
Registration of securities for employees
13 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Aug 21
Proxies
DEF 14A
Definitive proxy
14 Feb 23
DEF 14A
Definitive proxy
15 Apr 22
PRE 14A
Preliminary proxy
4 Apr 22
DEFA14A
Additional proxy soliciting materials
7 Jun 21
PX14A6G
Letter to shareholders
2 Jun 21
DEF 14A
Definitive proxy
10 May 21
PRE 14A
Preliminary proxy
30 Apr 21
DEF 14A
Definitive proxy
22 Apr 20
DEF 14A
Definitive proxy
30 Apr 19
PRE 14A
Preliminary proxy
5 Apr 19
Other
EFFECT
Notice of effectiveness
27 Mar 23
UPLOAD
Letter from SEC
30 Jan 23
CORRESP
Correspondence with SEC
19 Jan 23
UPLOAD
Letter from SEC
6 Jan 23
CORRESP
Correspondence with SEC
16 Dec 22
UPLOAD
Letter from SEC
7 Dec 22
SEC STAFF
SEC staff action: Order
18 Mar 21
SEC STAFF
SEC staff action: Order
18 Feb 21
EFFECT
Notice of effectiveness
3 Dec 20
CORRESP
Correspondence with SEC
30 Nov 20
Ownership
SC 13D/A
SPARKLE BYTE LTD
20 Feb 24
SC 13D/A
Ho Chi Sing
21 Feb 23
SC 13G/A
FEDERATED HERMES, INC.
9 Feb 23
SC 13G/A
FEDERATED HERMES, INC.
1 Feb 23
4
Alexander A Zukiwski
9 Sep 22
4
James Huang
8 Sep 22
4
James Huang
2 Sep 22
4
James Huang
26 Aug 22
4
James Huang
23 Aug 22
SC 13D/A
He Wei-Wu
21 Jun 22